Clinical trials · Raleigh–Durham, NC
HER2-Negative Breast Carcinoma clinical trials in Raleigh–Durham
We’re tracking 14 recruiting her2-negative breast carcinoma studies with a site in or near Raleigh–Durham — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Raleigh–Durham
- NCT07391774RecruitingPhase 3
Hormone therapy with or without chemo for early breast cancer
This trial tests whether skipping chemotherapy and using only hormone therapy with a drug called ribociclib works as well as chemotherapy followed by hormone therapy with ribociclib for certain early breast cancers that have a low risk of coming back.
Cary, North CarolinaAges 18 years+ - NCT06058377RecruitingPhase 3
Adding immunotherapy to chemo for stage II-III breast cancer
This trial tests whether adding the immunotherapy drug durvalumab to standard chemotherapy works better than chemo alone for people with hormone receptor positive, HER2 negative breast cancer that is stage II or III and has a high-risk genetic score (MammaPrint High Risk 2).
Cary, North CarolinaAges 18 years+ - NCT05812807RecruitingPhase 3
Pembrolizumab versus monitoring after triple-negative breast cancer response
This trial checks whether giving pembrolizumab (an immunotherapy) after surgery helps people with triple-negative breast cancer reduce the chance of the cancer coming back, compared with close monitoring only. It’s for patients who had no remaining invasive cancer after neoadjuvant chemotherapy plus pembrolizumab.
Cary, North CarolinaAges 18 years+ - NCT05564377RecruitingPhase 2
Find targeted cancer treatments using genetic testing
This study matches people with advanced solid tumors to targeted treatment plans based on genetic testing. It also requires tumor sample testing to help doctors choose the most promising therapy for your specific tumor changes.
Raleigh, North CarolinaAges Any age - NCT04893109RecruitingPhase 2
Study compares two HER2 breast cancer treatments after surgery
This Phase 2 study tests two different medicines given after breast surgery to reduce the risk of cancer coming back. It is only for people with early-stage HER2-positive breast cancer with limited or no lymph node spread.
Raleigh, North CarolinaAges 18 years+ - NCT06176261RecruitingPhase 2
Datopotamab deruxtecan for breast cancer with brain spread
This trial tests a new drug called datopotamab deruxtecan for people with HER2-negative breast cancer that has spread to the brain. It looks at how well the drug works against brain metastases.
Durham, North CarolinaAges 18 years+ - NCT06774027Recruiting
Breast cancer antibody-drug conjugate treatment registry
This study tracks how well antibody-drug conjugates (ADCs) work for breast cancer that has spread. You may join if you are about to start your first or second ADC for hormone receptor-positive/HER2-negative or triple-negative breast cancer.
Durham, North CarolinaAges 18 years+ - NCT04585750RecruitingPhase 1/Phase 2
Studying a new drug for cancers with a specific TP53 change
This trial tests a new drug (rezatapopt) for people with advanced cancers that have a specific change in the TP53 gene, called Y220C. The drug is designed to target this change and may slow or stop cancer growth. Some participants may also receive an immunotherapy drug called pembrolizumab (Keytruda).
Durham, North CarolinaAges 12 years+ - NCT06120283RecruitingPhase 1
Study of BGB-43395 alone or with other drugs for advanced solid tumors
This study tests a new drug called BGB-43395 alone or with other treatments for advanced solid tumors, especially breast cancer. The goal is to find the best dose and see how well it works. It may be an option if your cancer has not responded to other treatments.
Durham, North CarolinaAges 18 years+ - NCT06790693RecruitingPhase 3
Inavolisib plus hormone therapy for advanced breast cancer
This trial tests a new targeted therapy, inavolisib, combined with standard hormone therapy and a CDK4/6 inhibitor for people with a specific genetic mutation (PIK3CA) in their hormone receptor-positive, HER2-negative advanced breast cancer that has not been treated before. It compares this combination to a placebo plus the same standard treatments.
Durham, North CarolinaAges 18 years+ - NCT05501704RecruitingPhase 2
Testosterone-blocking therapy for male breast cancer
This Phase 2 study tests an oral treatment (called “ET”) to treat hormone-receptor–positive, HER2-negative invasive breast cancer in men. It may help shrink or control cancer without using standard cancer treatments first.
Chapel Hill, North CarolinaAges 18 years+ - NCT06179303RecruitingPhase 2
Imaging to predict response to abemaciclib for advanced breast cancer
This trial tests if a special PET scan can predict how well the drug abemaciclib works for people with advanced hormone receptor-positive, HER2-negative breast cancer. If you qualify, you would receive abemaciclib and have imaging scans to see if your cancer responds.
Chapel Hill, North CarolinaAges 18 years+ - NCT05929768RecruitingPhase 3
Shorter chemo plus immunotherapy without anthracyclines for early TNBC
This Phase 3 trial tests whether a shorter course of chemotherapy plus immunotherapy can work as well as standard treatment for early-stage triple-negative breast cancer. It avoids anthracycline drugs and may help reduce exposure to those medicines if the shorter plan is effective and safe.
Chapel Hill, North CarolinaAges 18 years+ - NCT07276880RecruitingPhase 2
Chemo, immunotherapy, and radiation for lymph node-positive triple-negative breast cancer
This trial tests a combination of chemotherapy, the immunotherapy drug pembrolizumab, and low or high-dose radiation before surgery for people with triple-negative breast cancer that has spread to the lymph nodes. The goal is to see if this approach can improve treatment outcomes.
Chapel Hill, North CarolinaAges 18 years+
Hear when a new HER2-Negative Breast Carcinoma trial opens near Raleigh–Durham, NC
We’ll email you when one opens near Raleigh–Durham, NC — at most once a week, no account needed, unsubscribe anytime.
HER2-Negative Breast Carcinoma trials in other cities
Where these studies are running near Raleigh–Durham
Institutions with a site for the recruiting her2-negative breast carcinoma studies listed above.
- Duke University Medical Center · 9 studies
- Duke Women's Cancer Care Raleigh · 4 studies
- UNC Lineberger Comprehensive Cancer Center · 4 studies
- Cone Health Cancer Center at Alamance Regional · 3 studies
- Duke Cancer Center Cary · 2 studies
- UNC Health Cancer Care Cary · 2 studies
- UNC Health Cancer Care Garner · 2 studies
- UNC Health Cancer Care Raleigh · 2 studies
What taking part in a her2-negative breast carcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting her2-negative breast carcinoma studies in North Carolina.
Common questions
- Are there her2-negative breast carcinoma clinical trials near Raleigh–Durham?
- Yes. We're currently tracking 14 recruiting her2-negative breast carcinoma studies with a site near Raleigh–Durham, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a her2-negative breast carcinoma study near Raleigh–Durham?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Raleigh–Durham to take part?
- Not necessarily. These studies have a site near Raleigh–Durham, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a her2-negative breast carcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New her2-negative breast carcinoma studies open near Raleigh–Durham regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.